Mitochondrial hepatopathies

Liver Disease in Children, Third Edition

Volumn , Issue , 2007, Pages 803-829

  Sokol, Ronald J ^a,b  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77958145877     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511547409.035     Document Type: Chapter

References (159)

1. Johns DR. Seminars in medicine of the Beth Israel Hospital, Boston. Mitochondrial DNA and disease. N Engl J Med 1995;333:638–44.
2. Treem WR, Sokol RJ. Disorders of the mitochondria. Semin Liver Dis 1998;18:237–53.
3. Bernes SM, Bacino C, Prezant TR, et al. Identical mitochondrial DNA deletion in mother with progressive external ophthalmoplegia and son with Pearson marrow-pancreas syndrome. J Pediatr 1993;123:598–602.
4. Ballinger SW, Shoffner JM, Gebhart S, et al. Mitochondrial diabetes revisited. Nat Genet 1994;7:458–9.
5. Hirano M, Silvestri G, Blake DM, et al. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder. Neurology 1994;44:721–7.
6. Beal MF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci 1993;16:125–31.
7. Wallace DC. Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science 1992;256:628–32.
8. Lightowlers RN, Chinnery PF, Turnbull DM, Howell N. Mammalian mitochondrial genetics: heredity, heteroplasmy and disease. Trends Genet 1997;13:450–5.
9. Poulton J, Macaulay V, Marchington DR. Mitochondrial genetics ’98 is the bottleneck cracked? Am J Hum Genet 1998;62: 752–7.
10. Taanman JW. The mitochondrial genome: structure, transcription, translation and replication. Biochim Biophys Acta 1999;1410:103–23.
11. Leonard JV, Schapira AH. Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects. Lancet 2000;355:389–94.
12. Susin SA, Zamzami N, Kroemer G. Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta 1998;1366:151–65.
13. Chinnery PF, Turnbull DM. Mitochondrial DNA and disease. Lancet 1999;354 Suppl 1:SI17–21.
14. Aprille JR. Mitochondrial cytopathies and mitochondrial DNA mutations. Curr Opinion Pediatr 1991;3:1045–54.
15. Munnich A. The respiratory chain. In: Fernandes J, Saudurray JM, eds. Inborn metabolic diseases: diagnosis and treatment. Berlin: Springer-Verlag, 1995:121–31.
16. Wallace DC. Mitochondrial DNA mutations in diseases of energy metabolism. J Bioenerg Biomembr 1994;26:241–50.
17. Holt IJ, Harding AE, Morgan-Hughes JA. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988;331:717–19.
18. Wallace DC, Singh G, Lott MT, et al. Mitochondrial DNAmutation associated with Leber’s hereditary optic neuropathy. Science 1988;242:1427–30.
19. Chinnery PF, Howell N, Andrews RM, Turnbull DM. Mitochondrial DNA analysis: polymorphisms and pathogenicity. J Med Genet 1999;36:505–10.
20. Chinnery PF, Johnson MA, Wardell TM, et al. The epidemiology of pathogenic mitochondrial DNA mutations. Ann Neurol 2000;48:188–93.
21. Darin N, Oldfors A, Moslemi AR, et al. The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA anbormalities. Ann Neurol 2001;49:377–83.
22. Majamaa K, Moilanen JS, Uimonen S, et al. Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: prevalence of the mutation in an adult population. Am J Hum Genet 1998;63:447–54.
23. Uusimaa J, Remes AM, Rantala H, et al. Childhood encephalopathies andmyopathies: a prospective study in a defined population to assess the frequency of mitochondrial disorders. Pediatrics 2000;105:598–603.
24. Chinnery PF, Turnbull DM. Epidemiology and treatment of mitochondrial disorders. Am J Med Genet 2001;106:94–101.
25. van den Heuvel L, Ruitenbeek W, Smeets R, et al. Demonstration of a new pathogenic mutation in human complex I deficiency: a 5-bp duplication in the nuclear gene encoding the 18-k D (AQDQ) subunit. Am J Hum Genet 1998;62:262–8.
26. Schuelke M, Smeitink J, Mariman E, et al. Mutant NDUFV1 subunit of mitochondrial complex I causes leukodystrophy and myoclonic epilepsy. Nat Genet 1999;21:260–1.
27. Briones P, Vilaseca MA, Ribes A, et al. A new case of multiple mitochondrial enzyme deficiencies with decreased amount of heat shock protein 60. J Inherit Metab Dis 1997;20(4):569–577.
28. Koehler CM, Leuenberger D, Merchant S, et al. Human deafness dystonia syndrome is a mitochondrial disease. Proc Natl Acad Sci U S A 1999;96:2141–6.
29. Zhu Z, Yao J, Johns T, et al. SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome. Nat Genet 1998;20:337–43.
30. Bakker HD, Scholte HR, Dingemans KP, et al. Depletion of mitochondrial deoxyribonucleic acid in a family with fatal neonatal liver disease. J Pediatr 1996;128:683–7.
31. Bioulac-Sage P, Parrot-Roulaud F, Mazat JP, et al. Fatal neonatal liver failure and mitochondrial cytopathy (oxidative phosphorylation deficiency): a light and electron microscopic study of the liver. Hepatology 1993;18:839–46.
32. Cormier V, Rustin P, Bonnefont JP, et al. Hepatic failure in disorders of oxidative phosphorylation with neonatal onset. J Pediatr 1991;119:951–4.
33. Cormier-Daire V, Chretien D, Rustin P, et al. Neonatal and delayed-onset liver involvement in disorders of oxidative phosphorylation. J Pediatr 1997;130:817–22.
34. Fayon M, Lamireau T, Bioulac-Sage P, et al. Fatal neonatal liver failure and mitochondrial cytopathy: an observation with antenatal ascites. Gastroenterology 1992;103:1332–5.
35. Mazzella M, Cerone R, Bonacci W, et al. Severe complex I deficiency in a case of neonatal-onset lactic acidosis and fatal liver failure. Acta Paediatr 1997;86:326–9.
36. Munnich A, Rotig A, Chretien D, et al. Clinical presentation of mitochondrial disorders in childhood. J Inherit Metab Dis 1996;19:521–7.
37. Vilaseca MA, Briones P, Ribes A, et al. Fatal hepatic failure with lactic acidaemia, Fanconi syndrome and defective activity of succinate:cytochrome c reductase. J Inherit Metab Dis 1991;14:285–8.
38. von Kleist-Retzow JC, Cormier-Daire V, Viot G, et al. Antenatal manifestations of mitochondrial respiratory chain deficiency. J Pediatr 2003;143:208–12.
39. Thomson M, Mc Kiernan P, Buckels J, et al. Generalised mitochondrial cytopathy is an absolute contraindication to orthotopic liver transplant in childhood. J Pediatr Gastroenterol Nutr 1998;26:478–81.
40. Sokal EM, Sokol R, Cormier V, et al. Liver transplantation in mitochondrial respiratory chain disorders. Eur J Pediatr 1999;158 Suppl 2:S81–4.
41. Goncalves I, Hermans D, Chretien D, et al. Mitochondrial respiratory chain defect: a new etiology for neonatal cholestasis and early liver insufficiency. J Hepatol 1995;23:290–4.
42. Valnot I, Osmond S, Gigarel N, et al. Mutations of the SCO1 gene in mitochondrial cytochrome c oxidase deficiency with neonatal-onset hepatic failure and encephalopathy. Am J Hum Genet 2000;67:1104–9.
43. Chabrol B, Mancini J, Chretien D, et al. Valproate-induced hepatic failure in a case of cytochrome c oxidase deficiency. Eur J Pediatr 1994;153:133–5.
44. de Lonlay P, Valnot I, Barrientos A, et al. A mutant mitochondrial respiratory chain assembly protein causes complex III deficiency in patients with tubulopathy, encephalopathy and liver failure. Nat Genet 2001;29:57–60.
45. De Meirleir L, Seneca S, Damis E, et al. Clinical and diagnostic characteristics of complex III deficiency due tomutations in the BCS1L gene. Am J Med Genet A 2003;121:126–31.
46. Ducluzeau PH, Lachaux A, Bouvier R, et al. Depletion of mitochondrial DNA associated with infantile cholestasis and progressive liver fibrosis. J Hepatol 1999;30:149–55.
47. Maaswinkel-Mooij PD, Van den Bogert C, Scholte HR, et al. Depletion of mitochondrial DNA in the liver of a patient with lactic acidemia and hypoketotic hypoglycemia. J Pediatr 1996;128:679–83.
48. Mazziotta MR, Ricci E, Bertini E, et al. Fatal infantile liver failure associated with mitochondrial DNA depletion. J Pediatr 1992;121:896–901.
49. Muller-Hocker J, Muntau A, Schafer S, et al. Depletion of mitochondrial DNA in the liver of an infant with neonatal giant cell hepatitis. Hum Pathol 2002;33:247–53.
50. Moraes CT, Shanske S, Tritschler HJ, et al. mt DNA depletion with variable tissue expression: a novel genetic abnormality in mitochondrial diseases. Am J Hum Genet 1991;48:492–501.
51. Tsao CY, Mendell JR, Luquette M, et al. Mitochondrial DNA depletion in children. J Child Neurol 2000;15:822–4.
52. Morris AA, Taanman JW, Blake J, et al. Liver failure associated with mitochondrial DNA depletion. J Hepatol 1998;28:556–63.
53. Mandel H, Hartman C, Berkowitz D, et al. The hepatic mitochondrial DNA depletion syndrome: ultrastructural changes in liver biopsies. Hepatology 2001;34:776–84.
54. Durand P, Debray D, Mandel R, et al. Acute liver failure in infancy: a 14-year experience of a pediatric liver transplantation center. J Pediatr 2001;139:871–6.
55. Bodnar AG, Cooper JM, Holt IJ, et al. Nuclear complementation restores mt DNA levels in cultured cells from a patient with mt DNA depletion. Am J Hum Genet 1993;53:663–9.
56. Taanman JW, Bodnar AG, Cooper JM, et al. Molecular mechanisms in mitochondrial DNA depletion syndrome. Hum Mol Genet 1997;6:935–42.
57. Jullig M, Eriksson S. Mitochondrial and submitochondrial localization of human deoxyguanosine kinase. Eur J Biochem 2000;267:5466–72.
58. Wang L, Munch-Petersen B, Herrstrom Sjoberg A, et al. Human thymidine kinase 2: molecular cloning and characterisation of the enzymeactivitywith antiviral and cytostatic nucleoside substrates. FEBS Lett 1999;443:170–4.
59. Mandel H, Szargel R, Labay V, et al. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet 2001;29:337–41.
60. Saada A, Shaag A, Mandel H, et al. Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet 2001;29:342–4.
61. Salviati L, Sacconi S, Mancuso M, et al. Mitochondrial DNA depletion and d GK gene mutations. Ann Neurol 2002;52:311–17.
62. Ferrari G, Lamantea E, Donati A, et al. Infantile hepatocerebral syndromes associated withmutations in the mitochondrial DNA polymerase-gamma A. Brain 2005;128:723–31.
63. Horvath R, Hudson G, Ferrari G, et al. Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. Brain 2006;129:1674–84.
64. Naviaux RK, Nguyen KV. POLG mutations associated with Alpers’ syndromeand mitochondrial DNAdepletion. Ann Neurol 2004;55:706–12.
65. Spinazzola A, Viscomi C, Fernandez-Vizarra E, et al. MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nat Genet 2006;38:570–5.
66. Alpers BJ. Diffuse progressive degeneration of the gray matter of the cerebrum. Arch Neurol Psychiatr 1931;25:469–505.
67. Boyd SG, Harden A, Egger J, Pampiglione G. Progressive neuronal degeneration of childhoodwith liver disease (“Alpers’ disease”): characteristic neurophysiological features. Neuropediatrics 1986;17:75–80.
68. Egger J, Harding BN, Boyd SG, et al. Progressive neuronal degeneration of childhood (PNDC) with liver disease. Clin Pediatr 1987;26:167–73.
69. Harding BN. Progressive neuronal degeneration of childhood with liver disease (Alpers–Huttenlocher syndrome): a personal review. J Child Neurol 1990;5:273–87.
70. Harding BN, Egger J, Portmann B, Erdohazi M. Progressive neuronal degeneration of childhoodwith liver disease. Apathological study. Brain 1986;109:181–206.
71. Hattenlocher PR, Solitare GB, Adams G. Infantile diffuse cerebral degeneration with hepatic cirrhosis. Arch Neurol 1976; 33:186–92.
72. Tulinius MH, Holme E, Kristiansson B, et al. Mitochondrial encephalomyopathies in childhood. I. Biochemical and morphologic investigations. J Pediatr 1991;119:242–50.
73. Nguyen KV, Sharief FS, Chan SS, et al. Molecular diagnosis of Alpers syndrome. J Hepatol 2006;45:108–16.
74. Narkewicz MR, Sokol RJ, Beckwith B, et al. Liver involvement in Alpers disease. J Pediatr 1991;119:260–7.
75. Wilson DC, Mc Gibben D, Hicks EM, Allen IV. Progressive neuronal degeneration of childhood (Alpers syndrome) with hepatic cirrhosis. Eur J Pediatr 1993;152:260–2.
76. Bicknese AR, May W, Hickey WF, Dodson WE. Early childhood hepatocerebral degeneration misdiagnosed as valproate hepatotoxicity. Ann Neurol 1992;32:767–75.
77. Davidzon G, Mancuso M, Ferraris S, et al. POLGmutations and Alpers syndrome. Ann Neurol 2005;57:921–3.
78. Pearson HA, Lobel JS, Kocoshis SA, et al. A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction. J Pediatr 1979;95:976–84.
79. Morikawa Y, Matsuura N, Kakudo K, et al. Pearson’s marrow/pancreas syndrome: a histological and genetic study. Virchows Arch A Pathol Anat Histopathol 1993;423:227–31.
80. Rotig A, Cormier V, Blanche S, et al. Pearson’smarrow–pancreas syndrome. A multisystem mitochondrial disorder in infancy. J Clin Invest 1990;86:1601–8.
81. Sano T, Ban K, Ichiki T, et al. Molecular and genetic analyses of two patients with Pearson’s marrow-pancreas syndrome. Pediatr Res 1993;34:105–10.
82. Tulinius MH, Holme E, Kristiansson B, et al. Mitochondrial encephalomyopathies in childhood. II. Clinical manifestations and syndromes. J Pediatr 1991;119:251–9.
83. Mc Shane MA, Hammans SR, Sweeney M, et al. Pearson syndrome and mitochondrial encephalomyopathy in a patientwith a deletion of mt DNA. Am J Hum Genet 1991;48:39–42.
84. Cormier-Daire V, Bonnefont JP, Rustin P, et al. Mitochondrial DNA rearrangements with onset as chronic diarrhea with villous atrophy. J Pediatr 1994;124:63–70.
85. Ionasescu V, Thompson SH, Ionasescu R, et al. Inherited ophthalmoplegia with intestinal pseudo-obstruction. J Neurol Sci 1983;59:215–28.
86. Hirano M, Vu TH. Defects of intergenomic communication: where do we stand? Brain Pathol 2000;10:451–61.
87. Cervera R, Bruix J, Bayes A, et al. Chronic intestinal pseudoobstruction and ophthalmoplegia in a patient with mitochondrial myopathy. Gut 1988;29:544–7.
88. Li V, Hostein J, Romero NB, et al. Chronic intestinal pseudoobstruction withmyopathy and ophthalmoplegia. Amuscular biochemical study of a mitochondrial disorder. Dig Dis Sci 1992;37:456–63.
89. Teitelbaum JE, Berde CB, Nurko S, et al. Diagnosis and management of MNGIE syndrome in children: case report and review of the literature. J Pediatr Gastroenterol Nutr 2002;35:377–83.
90. Hirano M, Garcia-de-Yebenes J, Jones AC, et al. Mitochondrial neurogastrointestinal encephalomyopathy syndrome maps to chromosome 22q13. 32-qter. Am J Hum Genet 1998;63:526–33.
91. Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 1999;283:689–92.
92. Nishino I, Spinazzola A, Papadimitriou A, et al. Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol 2000;47:792–800.
93. Brown NS, Bicknell R. Thymidine phosphorylase, 2-deoxy-Dribose and angiogenesis. Biochem J 1998;334:1–8.
94. Spinazzola A, Marti R, Nishino I, et al. Altered thymidine metabolism due to defects of thymidine phosphorylase. J Biol Chem 2002;277:4128–33.
95. Giordano C, Sebastiani M, Plazzi G, et al. Mitochondrial neurogastrointestinal encephalomyopathy: evidence of mitochondrial DNA depletion in the small intestine. Gastroenterology 2006;130:893–901.
96. Appenzeller O, Kornfeld M, Snyder R. Acromutilating, paralyzing neuropathy with corneal ulceration in Navajo children. Arch Neurol 1976;33:733–8.
97. Singleton R, Helgerson SD, Snyder RD, et al. Neuropathy in Navajo children: clinical and epidemiologic features. Neurology 1990;40:363–7.
98. Holve S, Hu D, Shub M, et al. Liver disease in Navajo neuropathy. J Pediatr 1999;135:482–93.
99. Vu TH, Tanji K, Holve SA, et al. Navajo neurohepatopathy: a mitochondrial DNA depletion syndrome? Hepatology 2001; 34:116–20.
100. Karadimas CL, Vu TH, Holve SA, et al. Navajo neurohepatopathy is caused by a mutation in the MPV17 gene. Am J Hum Genet 2006;79:544–8.
101. Treem WR. Inborn defects in mitochondrial fatty acid oxidation. In: Suchy FJ, ed. Liver disease in childhood. St. Louis, MO: Mosby, 1994:852–87.
102. Ventura FV, Ruiter JP, Ijlst L, et al. Inhibitory effect of 3-hydroxyacyl-Co As and other long-chain fatty acid betaoxidation intermediates on mitochondrial oxidative phosphorylation. J Inherit Metab Dis 1996;19:161–4.
103. Enns GM, Bennett MJ, Hoppel CL, et al. Mitochondrial respiratory chain complex I deficiency with clinical and biochemical features of long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. J Pediatr 2000;136:251–4.
104. Sims HF, Brackett JC, Powell CK, et al. The molecular basis of pediatric long chain 3-hydroxyacyl-Co A dehydrogenase deficiency associated with maternal acute fatty liver of pregnancy. Proc Natl Acad Sci U S A 1995;92:841–5.
105. Treem WR, Shoup ME, Hale DE, et al. Acute fatty liver of pregnancy, hemolysis, elevated liver enzymes, and low platelets syndrome, and long chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. Am J Gastroenterol 1996;91:2293–300.
106. Glasgow JF, Middleton B, Moore R, et al. The mechanism of inhibition of beta-oxidation by aspirin metabolites in skin fibroblasts from Reye’s syndrome patients and controls. Biochim Biophys Acta 1999;1454:115–25.
107. Belay ED, Bresee JS, Holman RC, et al. Reye’s syndrome in the United States from 1981 through 1997. N Engl J Med 1999; 340:1377–82.
108. De Vivo DC. Reye syndrome: a metabolic response to an acute mitochondrial insult? Neurology 1978;28:105–8.
109. Partin JC. Reye’s Syndrome. In: Suchy FJ, ed. Liver disease in children. St. Louis, MO: Mosby, 1994:653–71.
110. Heubi JE, Daugherty CC, Partin JS, et al. Grade I Reye’s syndrome – outcome and predictors of progression to deeper coma grades. N Engl J Med 1984;311:1539–42.
111. Partin JC, Schubert WK, Partin JS. Mitochondrial ultrastructure in Reye’s syndrome (encephalopathy and fatty degeneration of the viscera). N Engl J Med 1971;285:1339–43.
112. Hou JW, Chou SP, Wang TR. Metabolic function and liver histopathology in Reye-like illnesses. Acta Paediatr 1996;85: 1053–7.
113. Orlowski JP. Whatever happened to Reye’s syndrome? Did it ever really exist? Crit Care Med 1999;27:1582–7.
114. Hall SM, Lynn R. Reye’s syndrome. N Engl J Med 1999;341: 845–6; author reply 846–7.
115. Sternlieb I. Mitochondrial and fatty changes in hepatocytes of patients with Wilson’s disease. Gastroenterology 1968;55: 354–67.
116. Sternlieb I, Feldmann G. Effects of anticopper therapy on hepatocellular mitochondria in patients with Wilson’s disease: an ultrastructural and stereological study. Gastroenterology 1976;71:457–61.
117. Sokol RJ, Devereaux MW, O’Brien K, et al. Abnormal hepatic mitochondrial respiration and cytochrome C oxidase activity in rats with long-term copper overload. Gastroenterology 1993;105:178–87.
118. Sokol RJ, Twedt D, Mc Kim JM Jr, et al. Oxidant injury to hepatic mitochondria in patients with Wilson’s disease and Bedlington terrierswith copper toxicosis. Gastroenterology 1994;107:1788–98.
119. Mansouri A, Gaou I, Fromenty B, et al. Premature oxidative aging of hepatic mitochondrial DNA in Wilson’s disease. Gastroenterology 1997;113:599–605.
120. Lutsenko S, Cooper MJ. Localization of the Wilson’s disease protein product to mitochondria. Proc Natl Acad Sci U S A 1998;95:6004–9.
121. Mahler H, Pasi A, Kramer JM, et al. Fulminant liver failure in association with the emetic toxin of Bacillus cereus. N Engl J Med 1997;336:1142–8.
122. Fromenty B, Grimbert S, Mansouri A, et al. Hepatic mitochondrial DNA deletion in alcoholics: association with microvesicular steatosis. Gastroenterology 1995;108:193–200.
123. Mc Kenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl JMed 1995;333:1099–105.
124. Cui L, Yoon S, Schinazi RF, Sommadossi JP. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy- 2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest 1995;95:555–63.
125. Swartz MN. Mitochondrial toxicity–new adverse drug effects. N Engl J Med 1995;333:1146–8.
126. Lo JC, Kazemi MR, Hsue PY, et al. The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Dis 2005;41:1335–40.
127. Claessens YE, Chiche JD, Mira JP, Cariou A. Bench-to-bedside review: severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors. Crit Care 2003;7:226–32.
128. Sokol RJ, Winklhofer-Roob BM, Devereaux MW, Mc Kim JM, Jr. Generation of hydroperoxides in isolated rat hepatocytes and hepatic mitochondria exposed to hydrophobic bile acids. Gastroenterology 1995;109:1249–56.
129. Krahenbuhl S, Stucki J, Reichen J. Reduced activity of the electron transport chain in liver mitochondria isolated from rats with secondary biliary cirrhosis. Hepatology 1992;15:1160–6.
130. Krahenbuhl S, Talos C, Fischer S, Reichen J. Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria. Hepatology 1994;19:471–9.
131. Sokol R, Devereaux MW, Straka MS. Induction of the permeability transition in hepatic mitochondria by physiologic bile acid concentrations. Hepatology 1997;26:188A. 132.
132. Sokol RJ, Mc Kim JM, Jr., Goff MC, et al. Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. Gastroenterology 1998;114: 164–74.
133. Day CP, James OF. Hepatic steatosis: innocent bystander or guilty party? Hepatology 1998;27:1463–6.
134. Berson A, De Beco V, Letteron P, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998;114:764–74.
135. Lavine JE. Treatment of obesity-induced steatohepatitis with vitamin E. Gastroenterology 1998;114:A1284.
136. Munnich A, Rotig A, Chretien D, et al. Clinical presentations and laboratory investigations in respiratory chain deficiency. Eur J Pediatr 1996;155:262–74.
137. Rustin P, Chretien D, Bourgeron T, et al. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 1994;228:35–51.
138. Verma A, Piccoli DA, Bonilla E, et al. A novel mitochondrial G8313A mutation associated with prominent initial gastrointestinal symptoms and progressive encephaloneuropathy. Pediatr Res 1997;42:448–54.
139. Pitkanen S, Robinson BH. Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. J Clin Invest 1996;98:345–51.
140. Taivassalo T, Fu K, Johns T, et al. Gene shifting: a novel therapy for mitochondrial myopathy. Hum Mol Genet 1999;8:1047–52.
141. Clark KM, Bindoff LA, Lightowlers RN, et al. Reversal of a mitochondrial DNA defect in human skeletal muscle. Nat Genet 1997;16:222–4.
142. Taylor RW, Chinnery PF, Clark KM, et al. Treatment of mitochondrial disease. J Bioenerg Biomembr 1997;29:195–205.
143. Frei B, Kim MC, Ames BN. Ubiquinol-10 is an effective lipidsoluble antioxidant at physiological concentrations. Proc Natl Acad Sci U S A 1990;87:4879–83.
144. Sugino K, Dohi K, Yamada K, Kawasaki T. Changes in the levels of endogenous antioxidants in the liver of mice with experimental endotoxemia and the protective effects of the antioxidants. Surgery 1989;105:200–6.
145. Imada I, Fujita T, Sugiyama Y, et al. Effects of idebenone and related compounds on respiratory activities of brain mitochondria, and on lipid peroxidation of their membranes. Arch Gerontol Geriatr 1989;8:323–41.
146. Sugiyama Y, Fujita T. Stimulation of the respiratory and phosphorylating activities in rat brain mitochondria by idebenone (CV-2619), a new agent improving cerebral metabolism. FEBS Lett 1985;184:48–51.
147. Krahenbuhl S, Talos C, Lauterburg BH, Reichen J. Reduced antioxidative capacity in liver mitochondria from bile duct ligated rats. Hepatology 1995;22:607–12.
148. Hirano M, Quinzii CM, Dimauro S. Restoring balance to ataxia with coenzyme Q10 deficiency. J Neurol Sci 2006;246: 11–12.
149. Horvath R, Schneiderat P, Schoser BG, et al. Coenzyme Q10 deficiency and isolated myopathy. Neurology 2006;66:253–5.
150. Toth PP, el-Shanti H, Eivins S, et al. Transient improvement of congenital lactic acidosis in a male infant with pyruvate decarboxylase deficiency treated with dichloroacetate. J Pediatr 1993;123:427–30.
151. Rake JP, Van Spronsen FJ, Visser G. End-stage liver disease as the only consequence of a complex I and IV deficiency: liver transplantation indicated? J Inherit Metab Dis 1997;20 Suppl 1:65.
152. Starzl TE, Demetris AJ, Trucco M, et al. Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher’s disease. N Engl J Med 1993;328:745–9.
153. Manfredi G, Gupta N, Vazquez-Memije ME, et al. Oligomycin induces a decrease in the cellular content of a pathogenicmutation in the human mitochondrial ATPase 6 gene. J Biol Chem 1999;274:9386–91.
154. Seibel P, Trappe J, Villani G, et al. Transfection of mitochondria: strategy towards a gene therapy of mitochondrial DNAdiseases. Nucleic Acids Res 1995;23:10–17.
155. Taylor RW, Chinnery PF, Turnbull DM, Lightowlers RN. Selective inhibition of mutant human mitochondrial DNA replication in vitrobypeptidenucleic acids. Nat Genet 1997;15:212–15.
156. Schapira AH. Mitochondrial disease. Lancet 2006;368:70–82.
157. Ruitenbeek W, Wendel U, Hamel BC, Trijbels JM. Genetic counselling and prenatal diagnosis in disorders of the mitochondrial energy metabolism. J Inherit Metab Dis 1996;19:581–7.
158. Wanders RJ, Ruiter JP, Wijburg FA, et al. Prenatal diagnosis of systemic disorders of the respiratory chain in cultured chorionic villus fibroblasts by study of ATP-synthesis in digitonin-permeabilized cells. J Inherit Metab Dis 1996;19:133–6.
159. Muller-Hocker J, Aust D, Rohrbach H, et al. Defects of the respiratory chain in the normal human liver and in cirrhosis during aging. Hepatology 1997;26:709–19.